Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Atacand, Blopress, Candesartan; Belgium: Atacand; Cyprus: Atacand; Czech Republic: Atacand; Denmark: Amias, Atacand, Ratacand; Estonia: Atacand, Prescanden; Finland: Atacand; France: Atacand, Kenzen; Germany: Amias, Atacand, Blopress, Ratacand; Greece: Atacand; Hungary: Atacand; Ireland: Atacand, Catasart, Blopress; Italy: Blopress, Ratacand; Latvia: Atacand, Prescaden; Lithuania: Atacand; Luxembourg: Atacand; Malta: Atacand; Netherlands: Amias, Atacand, Blopress, Candesartan, Ratacand; Poland: Atacand, Blopress; Portugal: Atacand, Blopress, Candesartan; Romania: Atacand; Slovakia: Atacand, Candesartan; Slovenia: Atacand, Candea; Spain: Atacand, Blopress, Parapres; Sweden: Amias, Atacand, Blopress, Kenzen, Racanda, Ratacand; UK: Amias.

North America

Canada: Atacand; USA: Atacand.

Latin America

Argentina: Atacand, Dacten, Tiadyl; Mexico: Atacand, Blopress.


Japan: Blopress.

Drug combinations

Candesartan and Hydrochlorothiazide


Candesartan: C~24~H~20~N~6~O~3~. Mw: 440.45. (1) 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-; (2) 2-Ethoxy-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-7-benzimidazolecarboxylic acid. CAS-139481-59-7 (1997).

Candesartan Cilexetil: C~33~H~34~N~6~O~6~. Mw: 610.66. (±)-1-Hydroxyethyl 2-ethoxy-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester). CAS-145040-37-5 (1997).

Pharmacologic Category

Angiotensin II Receptor Antagonists. (ATC-Code: C09CA06).

Mechanism of action

Candesartan is an angiotensin receptor antagonist, blocking vasoconstriction and the aldosterone-secreting effects (reabsorption of sodium and water) of angiotensin II.

Therapeutic use

Essential hypertension. Heart failure.

Pregnancy and lactiation implications

Based on human data, drugs that act on the angiotensin system can cause injury and death to the developing fetus when used in the second and third trimesters. ACE inhibitors may also increase the risk of major congenital malformations when administered during the first trimester of pregnancy. Contraindicated during lactation.

Unlabeled use

Diabetic nephropathy.


Hypersensitivity to candesartan or any component of the formulation. Severe hepatic impairment and/or cholestasis. Pregnancy. Breast-feeding.

Warnings and precautions

Hyperkalemia might occur (risk factors: renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salts). May be associated with deterioration of renal function and/or increases in serum creatinine, resulting in oliguria, acute renal failure, and progressive azotemia. Use with caution in unstented unilateral/bilateral renal artery stenosis (if unstented bilateral renal artery stenosis is present, use is generally avoided unless possible benefits outweigh risks). Use with caution in significant aortic/mitral stenosis. Use with caution when initiating in heart failure. Hypotension may occur during major surgery and anesthesia. Avoid use or use smaller dose in patients who are volume-depleted. Use with caution in moderate hepatic impairment (contraindicated in severe hepatic impairment and/or cholestasis). Concurrent therapy with ACE inhibitor may be rational in selected patients.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart